FGF2 and prostate carcinoma: Specifically, we demonstrated that FGF2 secreted from endothelial cells can upregulate ERG expression in prostate cancer, which then activates the Akt/mTOR signaling pathway and promote docetaxel resistance of prostate cancer subsequently.